STAT+: Astellas withdraws lawsuit after evading Medicare drug price negotiations
WASHINGTON — Astellas was so sure that one of its drugs was going to be selected as part of Medicare’s new drug price negotiation program that the company preemptively sued the Biden administration.
But it turns out that its blockbuster drug Xtandi didn’t get picked for the program, after all. So on Wednesday, the company withdrew its lawsuit.
The decision underscores the unpredictability of the list of ten drugs Medicare chose for its first iteration of the negotiation program. Negotiated prices will go into effect in 2026.
